SAINT LAURENT, Quebec, Oct. 20, 2022 (GLOBE NEWSWIRE) — IntelGenx Corp. IGX IGXT (the “Company” or “IntelGenx”), a leading pharmaceutical film company, announced today that the United States Patent and Trademark Office (USPTO) has granted IntelGenx U.S. Patent No. 11,471,406, which covers claims on modulation of drug absorption in oral film dosage form Designed for sublingual administration of various drugs, including some cannabinoids.

This is the latest in a series of patents recently granted to IntelGenx and is expected to remain in effect until at least 2038, with no potential patent term extensions. The issuance of the ‘406 patent adds to the substantial intellectual property the company has built for its VersaFilm^® oral film technique. This patent will enable the development of a variety of proprietary products designed to improve drug delivery. While this novel proprietary technology, covered by both U.S. Patent #10,828,254 previously granted to IntelGenx in November 2020, and the new ‘406 patent for cannabis-infused oral films, particularly oral THC film dosage forms, the ‘406 patent specifically covers an oral film dosage form designed to modulate the absorption profile of sublingually administered drugs.

“We are pleased with the continued development of the patent portfolio protecting our VersaFilm^® oral film technology,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “This recent patent grant demonstrates our strong commitment to protecting the innovation of our technology portfolio and the significant commercial opportunity it represents for us and our partners.”

About IntelGenx

IntelGenx is a leading drug delivery company focused on developing and manufacturing pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm^®DisinteQ^™VetaFilm^™ and transdermal VevaDerm^™, enabling next-generation pharmaceutical products that address unmet medical needs. IntelGenxs…